1. Home
  2. RLI vs FOLD Comparison

RLI vs FOLD Comparison

Compare RLI & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RLI Corp. (DE)

RLI

RLI Corp. (DE)

HOLD

Current Price

$57.31

Market Cap

5.3B

Sector

Finance

ML Signal

HOLD

Logo Amicus Therapeutics Inc.

FOLD

Amicus Therapeutics Inc.

HOLD

Current Price

$14.47

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLI
FOLD
Founded
1965
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
4.5B
IPO Year
1994
2006

Fundamental Metrics

Financial Performance
Metric
RLI
FOLD
Price
$57.31
$14.47
Analyst Decision
Hold
Buy
Analyst Count
7
9
Target Price
$62.40
$27.25
AVG Volume (30 Days)
511.3K
2.3M
Earning Date
04-22-2026
05-06-2026
Dividend Yield
4.52%
N/A
EPS Growth
16.84
50.00
EPS
4.37
N/A
Revenue
$1,882,448,000.00
N/A
Revenue This Year
N/A
$20.50
Revenue Next Year
$3.53
$18.59
P/E Ratio
$13.39
N/A
Revenue Growth
6.33
N/A
52 Week Low
$55.80
$5.66
52 Week High
$78.25
$14.48

Technical Indicators

Market Signals
Indicator
RLI
FOLD
Relative Strength Index (RSI) 43.28 64.82
Support Level $55.86 $14.21
Resistance Level $59.31 $14.48
Average True Range (ATR) 1.21 0.02
MACD 0.10 -0.01
Stochastic Oscillator 18.86 60.00

Price Performance

Historical Comparison
RLI
FOLD

About RLI RLI Corp. (DE)

RLI Corp underwrites property and casualty insurance through its subsidiaries. The company offers insurance coverage in the specialty admitted market, where the products are designed for special risks. It also offers products in the excess and surplus markets, which provides an alternative for customers with risks or loss exposures that generally cannot be written in the standard admitted market. RLI distributes property and casualty insurance through its wholly-owned branch offices that market to wholesale and retail producers. The company's insurance operation segments include Casualty, Property, and Surety, and it derives a majority of its revenue from the Casualty segment.

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Share on Social Networks: